Affordable Access

Access to the full text

Development of β-elemene and Cisplatin Co-Loaded Liposomes for Effective Lung Cancer Therapy and Evaluation in Patient-Derived Tumor Xenografts

Authors
  • Cao, Mingxiang1
  • Long, Mengmeng1
  • Chen, Qiuping2
  • Lu, Yapeng1
  • Luo, Qianqian1
  • Zhao, Yue1
  • Lu, Ailing1
  • Ge, Cunwang1
  • Zhu, Li1
  • Chen, Zhongping1, 3
  • 1 Nantong University, Institute of Special Environmental Medicine, Nantong, People’s Republic of China , Nantong (China)
  • 2 Affiliated Hospital of Nantong University, Department of Anesthesiology, Nantong, People’s Republic of China , Nantong (China)
  • 3 University of Wisconsin-Madison, Pharmaceutical Sciences Division, School of Pharmacy, Madison, Wisconsin, USA , Madison (United States)
Type
Published Article
Journal
Pharmaceutical Research
Publisher
Springer-Verlag
Publication Date
Jun 18, 2019
Volume
36
Issue
8
Identifiers
DOI: 10.1007/s11095-019-2656-x
Source
Springer Nature
Keywords
License
Yellow

Abstract

Purposeβ-elemene and cisplatin combined chemotherapy currently is one of the most important settings available for lung cancer therapy in China. However, the clinical outcome is limited by their pharmacokinetic drawbacks. On the other hand, most of nanomedicines have failed in clinical development due to the huge differences between heterogeneous clinical tumor tissues and homogenous cell-derived xenografts. In this work, we fabricated a β-elemene and cisplatin co-loaded liposomal system to effectively treat lung cancer.MethodIn vitro cytotoxicity of co-loaded liposomes was studied by MTT, trypan and Hoechst/PI staining, and western blot in A549, A549/DDP, and LCC cells. In vivo antitumor efficacy was evaluated in cell-derived and clinically relevant patient-derived xenografts.ResultsCo-loaded liposomes were more cytotoxic to cancer cells, especially than the combination of single-loaded liposomes, benefiting from their simultaneous drug internalization and release. As a result, they exhibited desirable therapeutic outcome in both cell-derived and patient-derived xenografts.Conclusionβ-elemene and cisplatin co-loaded liposomes are a clinically promising candidate for effective lung cancer therapy.

Report this publication

Statistics

Seen <100 times